Clinical trials: Philadelphia-Negative ALL
- Condition Philadelphia-Negative ALL
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acute Lymphoblastic Leukemia, in Relapse
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also…
- Trial name
- GRASPIVOTALL (NCT01518517)
- Testing
- GRASPA, L-asparaginase
- Where
- 28 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- ERYtech Pharma
Relapsed/Refractory Acute Lymphoblastic Leukemia
An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
A retrospective chart review study of Philadelphia chromosome-negative R/R ALL patients in the US.
- Trial name
- NCT02783651
- Testing
- Other
- Where
- 19 sites in United States
- Volunteers
- 212 people
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.
- Trial name
- NCT02010931
- Where
- 10 sites in Czechia, France and 6 more
- Volunteers
- 310 people
- Sponsor
- Amgen